SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB

被引：0
|
作者：
Genovese, Mark C. [1 ]
Breedveld, Ferdinand C. [2 ]
Emery, Paul [3 ]
Cohen, Stanley B. [4 ]
Keystone, Edward [5 ]
Matteson, Eric L. [6 ]
Burke, Laura [7 ]
Chai, Akiko [8 ]
Reiss, William [8 ]
Sweetser, Marianne [9 ]
Shaw, Tim [7 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Leiden Univ, Leiden, Netherlands
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Metroplex Clin Res Ctr, Dallas, TX USA
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[6] Mayo Clin, Rochester, MN USA
[7] Roche, Prod Dev, Welwyn Garden City, Herts, England
[8] Genentech Inc, Stat, San Francisco, CA 94080 USA
[9] Biogen Idec Inc, Drug Safety, Cambridge, MA USA
来源：
RHEUMATOLOGY | 2011年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [1] Subsequent biologic therapy survival and reason for discontinuation in patients who have discontinued infliximab therapy
    Barnabe, Cheryl
    Barr, Susan
    Martin, Liam
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1207 - 1208
  • [2] Safety of Other Biologic Therapies Following Rituximab Treatment in RA Patients
    Khraishi, Majed
    Genovese, Mark C.
    Breedveld, Ferdinand
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2598 - 2599
  • [3] SAFETY OF OTHER BIOLOGIC THERAPIES FOLLOWING RITUXIMAB TREATMENT IN RA PATIENTS
    Genovese, Mark C.
    Breedveld, Ferdinand C.
    Emery, Paul
    Cohen, Stanley B.
    Keystone, Edward
    Matteson, Eric
    Baptiste, Yvette
    Burke, Laura
    Reiss, William
    Sweetser, Marianne
    Shaw, Tim
    RHEUMATOLOGY, 2009, 48 : I90 - I91
  • [4] Safety of other biologic therapies following rituximab treatment in RA patients
    Genovese, M.
    Breedveld, F.
    Emery, P.
    Cohen, S.
    Keystone, E.
    Matteson, E.
    Baptiste, Y.
    Burke, L.
    Reiss, W.
    Sweetser, M.
    Shaw, T.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S785 - S785
  • [5] Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
    Richa Mishra
    Vijay Singh
    Charles H. Pritchard
    Rheumatology International, 2011, 31 : 481 - 484
  • [6] Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
    Mishra, Richa
    Singh, Vijay
    Pritchard, Charles H.
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (04) : 481 - 484
  • [7] Is rituximab suitable for use as a first-line biologic therapy for RA?
    Kleiner, Anatole
    Looney, R. John
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (11): : 574 - 575
  • [8] Is rituximab suitable for use as a first-line biologic therapy for RA?
    Anatole Kleiner
    R John Looney
    Nature Clinical Practice Rheumatology, 2008, 4 : 574 - 575
  • [9] Characteristics of colorectal patients who discontinued oxaliplatin therapy.
    Buchholz, Alexander
    Sahmoun, Abe E.
    Kurniali, Peter C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Predictors of Mortality in RA Patients before Biologic Therapy
    Rosario, Debora Cordeiro
    Bulhoes, Camila Nobre
    Toledo, Rodrigo Peres
    Bonfiglioli, Karina
    Ribeiro, Ana C. M.
    Moraes, Julio C. B.
    Saad, Carla G. S.
    Silva, Clovis A.
    Bonfa, Eloisa
    Aikawa, Nadia E.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345